Skip to main content
This site is intended only for U.S. Healthcare Providers
Attention: Lilly Support Services™ and the healthcare Provider Portal for patient and savings card enrollment for CYRAMZA will end September 15th, 2026. Please see below for available support and download a savings card on behalf of commercially eligible and insured patients.

The CYRAMZA® Savings Card

Eligible, commercially insured covered patients pay as little as $25 a month for CYRAMZA®

By enrolling in the CYRAMZA® Savings Card Program (“Program”) and using the CYRAMZA® Savings Card (“Card”), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Eligibility:

  1. You have been prescribed CYRAMZA® (ramucirumab) for an approved use consistent with FDA-approved product labeling;
  2. You are enrolled in a commercial drug insurance plan and have coverage for CYRAMZA®;
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Card Terms and Conditions
You must (a) have commercial drug insurance that covers CYRAMZA®, but your insurance does not cover the full cost and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for each infusion. The Program will cover your co-pay or coinsurance for CYRAMZA® less $25. Card savings are subject to a maximum monthly savings of up to wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum annual savings of up to $25,000 per calendar year. Card may be used for a maximum of up to 12 infusions per calendar year. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs.

To receive Program savings, your healthcare provider must submit a claim for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim, your healthcare provider must then submit an Explanation of Benefits (EOB) form and a CMS 1450 or 1500 form to www.lillymedicalclaimsportal.com within 180 days of the infusion date of CYRAMZA®. The submitted form must include the name of the insurer and plan and demonstrate that CYRAMZA® was the medication administered. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program ("AFP") that requires you to apply to the CYRAMZA® Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of your prescribed Covered Medicine, you are not eligible for and are prohibited from using the CYRAMZA® Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly Products from coverage contingent upon a member's use of the CYRAMZA® Savings Card Program. You agree to inform the CYRAMZA® Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximums are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for CYRAMZA®, only allows partial coverage for CYRAMZA®, removes coverage for CYRAMZA® and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of CYRAMZA®, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for CYRAMZA®.

Program savings are limited to the co-pay or coinsurance costs for CYRAMZA® only, subject to monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the CYRAMZA® Savings Card Program. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving CYRAMZA®. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly's sole discretion to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card's eligibility criteria or is using or has attempted to use the Card inconsistently with these Terms and Conditions. Eligibility criteria, and terms and conditions for the CYRAMZA® Savings Card Program may change from time to time; the most current version can be found at https://cyramza.lilly.com/financial-support#full-terms-and-conditions . You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

OTHER TOOLS AND RESOURCES

Find other resources that may help you assist patients with reimbursement

When insurance isn't enough to pay for cancer treatment, there are other resources that may help address the financial challenges and access issues that some patients experience.

Lilly Cares® Foundation

The Lilly Cares Foundation, Inc., a separate nonprofit organization, offers a patient assistance program to help qualifying patients receive Lilly medications at no cost. For more information about Lilly Cares, please visit LillyCares.com.


Independent Patient-Assistance Program Foundations

There may be a way to help your underinsured patients get the treatment they need with less financial stress. If your patients can't afford their co-pay or coinsurance, Lilly Support Services provides information about a number of independent patient-assistance programs that may be able to help eligible patients. These foundations are not affiliated with Eli Lilly and Company and have been established and are operated independently. Please remember, funding availability changes weekly, so contact a Lilly Support Services representative at 1-800-LillyRx (1-800-545-5979) for the most recent updates.

View Foundation List

BILLING AND CODING

Find billing codes and information:

CYRAMZA® (ramucirumab)

ADDITIONAL RESOURCES

Find the resources you need to navigate the appeals process

There are other tools and resources that can help as you work through the ordering, billing, reimbursement, and appeals processes.

APPEALS RESOURCES

Find the resources you need to navigate the appeals process

If an insurance claim is denied, Lilly Support Services can provide information to help you file an appeal on your patient's behalf. We'll help you understand what documents and information you'll need and the deadlines you'll have to meet.

If you have questions about filing an appeal, please call us at 1-800-LillyRx (1-800-545-5979).


Denied Claims Checklist

If a patient receives a denied explanation of benefits or an unfavorable response to a previous appeal, use this checklist to help you prepare an appeal packet.

Download Checklist


Letter of Medical Necessity Information

This guide provides important information needed in your letter of medical necessity to help facilitate the appeal process.

Download Letter


First-Level Appeal Letter for Commercial or Other Insurance

Use this template to create a request letter for a first-level appeal by an oncology medical advisor.

Download Appeal Letter


Second-Level Appeal Letter for Commercial or Other Insurance

If your patient's first appeal was denied or he/she received an unfavorable response, use this letter template to initiate a second-level appeal.

Download Appeal Letter


First-Level Medicare Review Letter

If your patient was denied Medicare coverage, this letter template will help you request a redetermination by an oncology medical advisor.

Download Review Letter


Second-Level Medicare Review Letter

If your patient's first Medicare review resulted in a denial or an unfavorable response, use this letter template to initiate a second-level review.

Download Review Letter

IMPORTANT SAFETY INFORMATION

Hemorrhage - CYRAMZA® increased the risk of hemorrhage and gastrointestinal hemorrhage, including Grade ≥3 hemorrhagic events. In 2137 patients with various cancers treated with CYRAMZA®, the incidence of all Grade hemorrhage ranged from 13-55%. Grade 3-5 hemorrhage incidence ranged from 2-5%.

  • Patients with gastric cancer receiving nonsteroidal anti-inflammatory drugs (NSAIDs) were excluded from enrollment in REGARD and RAINBOW; therefore, the risk of gastric hemorrhage in CYRAMZA®-treated patients with gastric tumors receiving NSAIDs is unknown.
  • Patients with NSCLC receiving therapeutic anticoagulation or with evidence of major airway invasion by cancer were excluded from REVEL. In addition, patients with NSCLC with a recent history of gross hemoptysis, those receiving chronic therapy with NSAIDs or other anti-platelet therapy other than once daily aspirin or with radiographic evidence of major blood vessel invasion or intratumor cavitation were excluded from REVEL and RELAY; therefore the risk of pulmonary hemorrhage in these groups of patients is unknown.
  • Permanently discontinue CYRAMZA® in patients who experience severe (Grade 3 or 4) bleeding.

Gastrointestinal Perforations - CYRAMZA® can increase the risk of gastrointestinal perforation, a potentially fatal event. In 2137 patients with various cancers treated with CYRAMZA®, the incidence of all Grade and Grade 3-5 gastrointestinal perforations ranged from <1-2%.

  • Permanently discontinue CYRAMZA® in patients who experience a gastrointestinal perforation.

Impaired Wound Healing - CYRAMZA® has the potential to adversely affect wound healing. CYRAMZA® has not been studied in patients with serious or non-healing wounds.

  • Withhold CYRAMZA® for 28 days prior to elective surgery. Do not administer CYRAMZA® for at least 2 weeks following a major surgical procedure and until adequate wound healing. The safety of resumption of CYRAMZA® after resolution of wound healing complications has not been established.

Arterial Thromboembolic Events (ATEs) - Serious, sometimes fatal, ATEs, including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia, occurred across clinical trials. In 2137 patients with various cancers treated with CYRAMZA®, the incidence of all Grade ATE was 1-3%. Grade 3-5 ATE incidence was <1-2%.

  • Permanently discontinue CYRAMZA® in patients who experience an ATE.

Hypertension - An increased incidence of severe hypertension occurred in patients receiving CYRAMZA®. Across five clinical studies, excluding RELAY, in 1916 patients with various cancers treated with CYRAMZA®, the incidence of all Grade hypertension ranged from 11-26%. Grade 3-5 hypertension incidence ranged from 6-15%. In 221 patients with NSCLC receiving CYRAMZA® in combination with erlotinib in the RELAY study, the incidence of new or worsening hypertension was higher (45%), as was the incidence of Grade 3-5 hypertension (24%). Of the patients experiencing new or worsening hypertension in RELAY (N=100 CYRAMZA® and erlotinib; N=27 placebo and erlotinib), 13% of those treated with CYRAMZA® and erlotinib required initiation of 3 or more antihypertensive medications compared to 4% of patients treated with placebo and erlotinib.

  • Control hypertension prior to initiating treatment with CYRAMZA®. Monitor blood pressure every two weeks or more frequently as indicated during treatment. Withhold CYRAMZA® for severe hypertension until medically controlled. Permanently discontinue CYRAMZA® for medically significant hypertension that cannot be controlled with antihypertensive therapy or in patients with hypertensive crisis or hypertensive encephalopathy.

Infusion-Related Reactions (IRR) - including severe and life-threatening IRR, occurred in CYRAMZA® clinical trials. Symptoms of IRR included rigors/tremors, back pain/spasms, chest pain and/or tightness, chills, flushing, dyspnea, wheezing, hypoxia, and paresthesia. In severe cases, symptoms included bronchospasm, supraventricular tachycardia, and hypotension. In 2137 patients with various cancers treated with CYRAMZA® in which premedication was recommended or required, the incidence of all Grade IRR ranged from <1- 9%. Grade 3-5 IRR incidence was <1%.

  • Premedicate prior to each CYRAMZA® infusion. Monitor patients during the infusion for signs and symptoms of IRR in a setting with available resuscitation equipment. Reduce the infusion rate by 50% for Grade 1-2 IRR. Permanently discontinue CYRAMZA® for Grade 3- 4 IRR.

Worsening of Pre-existing Hepatic Impairment - Clinical deterioration, manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome, was reported in patients with Child-Pugh B or C cirrhosis who received single agent CYRAMZA®. Use CYRAMZA® in patients with Child-Pugh B or C cirrhosis only if the potential benefits of treatment are judged to outweigh the risks of clinical deterioration.

  • Based on safety data from REACH-2, in patients with Child-Pugh A liver cirrhosis, the pooled incidence of hepatic encephalopathy and hepatorenal syndrome was higher for patients who received CYRAMZA® (6%) compared to patients who received placebo (0%).

Posterior Reversible Encephalopathy Syndrome (PRES) - (also known as Reversible Posterior Leukoencephalopathy Syndrome [RPLS]) has been reported in <0.1% of 2137 patients with various cancers treated with CYRAMZA®. Symptoms of PRES include seizure, headache, nausea/vomiting, blindness, or altered consciousness, with or without associated hypertension.

  • Permanently discontinue CYRAMZA® in patients who develop PRES. Symptoms may resolve or improve within days, although some patients with PRES can experience ongoing neurologic sequelae or death.

Proteinuria Including Nephrotic Syndrome - In 2137 patients with various cancers treated with CYRAMZA®, the incidence of all Grade proteinuria ranged from 3-34%. Grade ≥3 proteinuria (including 4 patients with nephrotic syndrome) incidence ranged from <1-3%.

  • Monitor for proteinuria. Withhold CYRAMZA® for urine protein levels that are 2 or more grams over 24 hours. Reinitiate CYRAMZA® at a reduced dose once the urine protein level returns to less than 2 grams over 24 hours. Permanently discontinue CYRAMZA® for urine protein levels greater than 3 grams over 24 hours or in the setting of nephrotic syndrome.

Thyroid Dysfunction - In 2137 patients with various cancers treated with CYRAMZA®, the incidence of Grade 1-2 hypothyroidism ranged from <1-3%; there were no reports of Grade 3-5 hypothyroidism. Monitor thyroid function during treatment with CYRAMZA®.

Embryo-Fetal Toxicity - CYRAMZA® can cause fetal harm when administered to pregnant women. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with CYRAMZA® and for 3 months after the last dose.

Lactation - Because of the potential risk for serious adverse reactions in breastfed children from ramucirumab, advise women not to breastfeed during treatment with CYRAMZA® and for 2 months after the last dose.

Adverse Reactions

REGARD:

  • The most common adverse reactions (all Grades) observed in single agent CYRAMZA®-treated gastric cancer patients at a rate of ≥5% and ≥2% higher than placebo were hypertension (16% vs 8%), diarrhea (14% vs 9%), headache (9% vs 3%), and hyponatremia (6% vs 2%).
  • The most common serious adverse reactions with CYRAMZA® were anemia (3.8%) and intestinal obstruction (2.1%). Red blood cell transfusions were given to 11% of CYRAMZA®-treated patients vs 8.7% of patients who received placebo.
  • Clinically relevant adverse reactions reported in ≥1% and <5% of CYRAMZA®-treated patients in REGARD were: neutropenia (4.7%), epistaxis (4.7%), rash (4.2%), intestinal obstruction (2.1%), and arterial thromboembolic events (1.7%).
  • Across clinical trials of CYRAMZA® administered as a single agent, clinically relevant adverse reactions (including Grade ≥3) reported in CYRAMZA®-treated patients included proteinuria, gastrointestinal perforation, and IRR. In REGARD, according to laboratory assessment, 8% of CYRAMZA®-treated patients developed proteinuria vs 3% of placebo-treated patients. Two patients discontinued CYRAMZA® due to proteinuria. The rate of gastrointestinal perforation in REGARD was 0.8% and the rate of IRR was 0.4%.

RAINBOW:

  • The most common adverse reactions (all grades) observed in patients treated with CYRAMZA® with paclitaxel at a rate of ≥5% and ≥2% higher than placebo with paclitaxel were fatigue/asthenia (57% vs 44%), neutropenia (54% vs 31%), diarrhea (32% vs 23%), epistaxis (31% vs 7%), hypertension (25% vs 6%), peripheral edema (25% vs 14%), stomatitis (20% vs 7%), proteinuria (17% vs 6%), thrombocytopenia (13% vs 6%), hypoalbuminemia (11% vs 5%), and gastrointestinal hemorrhage events (10% vs 6%).
  • The most common serious adverse reactions with CYRAMZA® with paclitaxel were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of patients who received CYRAMZA® with paclitaxel received granulocyte colony-stimulating factors.
  • Adverse reactions resulting in discontinuation of any component of the CYRAMZA® with paclitaxel combination in ≥2% of patients in RAINBOW were neutropenia (4%) and thrombocytopenia (3%).
  • Clinically relevant adverse reactions reported in ≥1% and <5% of patients receiving CYRAMZA® with paclitaxel were sepsis (3.1%), including 5 fatal events, and gastrointestinal perforations (1.2%), including 1 fatal event.

REVEL:

  • The most common adverse reactions (all Grades) observed in patients treated with CYRAMZA® with docetaxel at a rate of ≥5% and ≥2% higher than placebo with docetaxel were neutropenia (55% vs 46%), fatigue/asthenia (55% vs 50%), stomatitis/mucosal inflammation (37% vs 19%), epistaxis (19% vs 7%), febrile neutropenia (16% vs 10%), peripheral edema (16% vs 9%), thrombocytopenia (13% vs 5%), lacrimation increased (13% vs 5%), and hypertension (11% vs 5%).
  • The most common serious adverse reactions with CYRAMZA® with docetaxel were febrile neutropenia (14%), pneumonia (6%), and neutropenia (5%). The use of granulocyte colony-stimulating factors was 42% in CYRAMZA® with docetaxel- treated patients versus 37% in patients who received placebo with docetaxel.
  • Treatment discontinuation due to adverse reactions occurred more frequently in CYRAMZA® with docetaxel-treated patients (9%) than in placebo with docetaxel-treated patients (5%). The most common adverse reactions leading to treatment discontinuation of CYRAMZA® were IRR (0.5%) and epistaxis (0.3%).
  • For patients with non-squamous histology, the overall incidence of pulmonary hemorrhage was 7% and the incidence of Grade ≥3 pulmonary hemorrhage was 1% for CYRAMZA® with docetaxel compared to 6% overall incidence and 1% for Grade ≥3 pulmonary hemorrhage for placebo with docetaxel. For patients with squamous histology, the overall incidence of pulmonary hemorrhage was 10% and the incidence of Grade ≥3 pulmonary hemorrhage was 2% for CYRAMZA® with docetaxel compared to 12% overall incidence and 2% for Grade ≥3 pulmonary hemorrhage for placebo with docetaxel.
  • Clinically relevant adverse reactions reported in ≥1% and <5% of CYRAMZA® with docetaxel-treated patients in REVEL were hyponatremia (4.8%) and proteinuria (3.3%).

RELAY:

  • The most common adverse reactions (all Grades) observed in patients treated with CYRAMZA® with erlotinib at a rate of ≥5% and ≥2% higher than placebo with erlotinib were infections (81% vs 76%), diarrhea (70% vs 71%), hypertension (45% vs 12%), stomatitis (42% vs 36%), alopecia (34% vs 20%), epistaxis (34% vs 12%), proteinuria (34% vs 8%), peripheral edema (23% vs 4%), headache (15% vs 7%), gastrointestinal hemorrhage (10% vs 3%), gingival bleeding (9% vs 1%), and pulmonary hemorrhage (7% vs 2%).
  • The most common serious adverse reactions with CYRAMZA® with erlotinib were pneumonia (3.2%), cellulitis (1.8%), and pneumothorax (1.8%). Red blood cell transfusions were given to 3.2% of CYRAMZA®-treated patients versus 0 patients who received placebo.
  • Treatment discontinuation of all study drugs due to adverse reactions occurred in 13% of CYRAMZA® with erlotinib-treated patients, with increased alanine aminotransferase (1.4%) and paronychia (1.4%) being the most common. The most common adverse reactions leading to treatment discontinuation of CYRAMZA® were proteinuria (8.6%) and hyperbilirubinemia (6%).
  • Of the 221 patients who received CYRAMZA® with erlotinib, 119 (54%) were 65 and over, while 29 (13%) were 75 and over. Adverse reactions occurring at a 10% or higher incidence in patients receiving CYRAMZA® with erlotinib and with a 10% or greater difference between patients aged 65 or older compared to patients aged less than 65 years were: diarrhea (75% versus 65%), hypertension (50% versus 40%), increased ALT (49% versus 35%), increased AST (49% versus 33%), stomatitis (46% versus 36%), decreased appetite (32% versus 19%), dysgeusia (23% versus 12%), and weight loss (19% versus 6%).

RAISE:

  • The most common adverse reactions (all Grades) observed in patients treated with CYRAMZA® with FOLFIRI at a rate of ≥5% and ≥2% higher than placebo with FOLFIRI were diarrhea (60% vs 51%), neutropenia (59% vs 46%), decreased appetite (37% vs 27%), epistaxis (33% vs 15%), stomatitis (31% vs 21%), thrombocytopenia (28% vs 14%), hypertension (26% vs 9%), peripheral edema (20% vs 9%), proteinuria (17% vs 5%), palmar-plantar erythrodysesthesia syndrome (13% vs 5%), gastrointestinal hemorrhage events (12% vs 7%), and hypoalbuminemia (6% vs 2%). Twenty percent of patients treated with CYRAMZA® with FOLFIRI received granulocyte colony- stimulating factors.
  • The most common serious adverse reactions with CYRAMZA® with FOLFIRI were diarrhea (3.6%), intestinal obstruction (3.0%), and febrile neutropenia (2.8%).
  • Treatment discontinuation of any study drug due to adverse reactions occurred more frequently in CYRAMZA® with FOLFIRI-treated patients (29%) than in placebo with FOLFIRI-treated patients (13%). The most common adverse reactions leading to discontinuation of any component of CYRAMZA® with FOLFIRI as compared to placebo with FOLFIRI were neutropenia (12.5% vs 5.3%) and thrombocytopenia (4.2% vs 0.8%). The most common adverse reactions leading to treatment discontinuation of CYRAMZA® were proteinuria (1.5%), and gastrointestinal perforation (1.7%).
  • Clinically relevant adverse reaction reported in ≥1% and <5% of patients receiving CYRAMZA® with FOLFIRI was gastrointestinal perforation (1.7%), including 4 fatal events.
  • Thyroid-stimulating hormone (TSH) levels were evaluated in 224 patients (115 CYRAMZA® with FOLFIRI-treated patients and 109 placebo with FOLFIRI-treated patients) with normal baseline TSH levels. Increased TSH levels were observed in 53 (46%) patients treated with CYRAMZA® with FOLFIRI compared with 4 (4%) patients treated with placebo with FOLFIRI.

REACH-2:

  • The most common adverse reactions (all Grades) observed in single agent CYRAMZA®-treated HCC patients at a rate of ≥10% and ≥2% higher than placebo were fatigue (36% vs 20%), peripheral edema (25% vs 14%), hypertension (25% vs 13%), abdominal pain (25% vs 16%), decreased appetite (23% vs 20%), proteinuria (20% vs 4%), nausea (19% vs 12%), ascites (18% vs 7%), headache (14% vs 5%), epistaxis (14% vs 3%), insomnia (11% vs 6%), pyrexia (10% vs 3%), vomiting (10% vs 7%), and back pain (10% vs 7%).
  • The most common serious adverse reactions with CYRAMZA® were ascites (3%) and pneumonia (3%).
  • Treatment discontinuations due to adverse reactions occurred in 18% of CYRAMZA®-treated patients, with proteinuria being the most frequent (2%).
  • Clinically relevant adverse reactions reported in ≥1% and <10% of CYRAMZA®-treated patients in REACH-2 were IRR (9%), hepatic encephalopathy (5%) including 1 fatal event, and hepatorenal syndrome (2%) including 1 fatal event.

Please click for full Prescribing Information for CYRAMZA®.

RB-P HCP ISI 14SEP2022

INDICATIONS

  • CYRAMZA® as a single agent, or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
  • CYRAMZA®, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
  • CYRAMZA®, in combination with docetaxel, is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Adults with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA®.
  • CYRAMZA®, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
  • CYRAMZA®, as a single agent, is indicated for the treatment of adults with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.